 Eloxx Pharmaceuticals, Inc. ELOX, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it will release its first quarter 2020 financial and operational results and host a conference call and live webcast on Thursday, May 7, 2020. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates designed to be eukaryotic ribosomal selective glycosides that are formulated to treat rare and ultra-rare premature stop codon diseases. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. 